Shares of Cidara Therapeutics Inc (NASDAQ:CDTX) have earned an average rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $13.25.

Several equities analysts recently weighed in on CDTX shares. ValuEngine lowered shares of Cidara Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, June 7th. WBB Securities raised shares of Cidara Therapeutics from a “hold” rating to a “buy” rating in a research report on Wednesday, May 23rd. Zacks Investment Research raised shares of Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research report on Tuesday, July 24th. Cantor Fitzgerald set a $15.00 price objective on shares of Cidara Therapeutics and gave the company a “buy” rating in a research report on Tuesday, September 4th. Finally, Citigroup started coverage on shares of Cidara Therapeutics in a research report on Wednesday, July 25th. They set a “buy” rating and a $8.00 price objective on the stock.

Institutional investors and hedge funds have recently modified their holdings of the stock. Trexquant Investment LP raised its position in shares of Cidara Therapeutics by 119.9% in the first quarter. Trexquant Investment LP now owns 32,845 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 17,912 shares during the period. Northern Trust Corp raised its position in shares of Cidara Therapeutics by 102.5% in the first quarter. Northern Trust Corp now owns 35,581 shares of the biotechnology company’s stock valued at $142,000 after purchasing an additional 18,014 shares during the period. JPMorgan Chase & Co. raised its position in shares of Cidara Therapeutics by 87.0% in the first quarter. JPMorgan Chase & Co. now owns 69,172 shares of the biotechnology company’s stock valued at $277,000 after purchasing an additional 32,181 shares during the period. Acadian Asset Management LLC raised its position in shares of Cidara Therapeutics by 113.6% in the second quarter. Acadian Asset Management LLC now owns 86,515 shares of the biotechnology company’s stock valued at $450,000 after purchasing an additional 46,019 shares during the period. Finally, Alethea Capital Management LLC raised its position in shares of Cidara Therapeutics by 40.1% in the second quarter. Alethea Capital Management LLC now owns 109,094 shares of the biotechnology company’s stock valued at $567,000 after purchasing an additional 31,198 shares during the period. 67.14% of the stock is currently owned by hedge funds and other institutional investors.

CDTX traded down $0.15 during midday trading on Thursday, hitting $4.15. 3,381 shares of the company’s stock traded hands, compared to its average volume of 125,064. The firm has a market cap of $117.63 million, a PE ratio of -1.32 and a beta of 1.99. The company has a debt-to-equity ratio of 0.12, a quick ratio of 7.11 and a current ratio of 7.11. Cidara Therapeutics has a one year low of $3.65 and a one year high of $8.80.

Cidara Therapeutics (NASDAQ:CDTX) last issued its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($0.66) by ($0.47). sell-side analysts anticipate that Cidara Therapeutics will post -2.53 earnings per share for the current fiscal year.

Cidara Therapeutics Company Profile

Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.

Featured Article: Understanding Price to Earnings Ratio (PE)

Analyst Recommendations for Cidara Therapeutics (NASDAQ:CDTX)

Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.